The STEP (Semaglutide Treatment Effect in People with obesity) trial program showed average weight reductions of approximately 15% of initial body weight over 68 weeks in individuals without diabetes, with somewhat lower reductions (about 9-10%) in those with type 2 diabetes
[5] [6] For weight management, NICE technology appraisals (TA664 for semaglutide/Wegovy and TA662 for liraglutide/Saxenda) recommend use only within specialist weight management services for people meeting specific BMI thresholds with weight-related comorbidities
PlexusDx serves all 50 states without requiring insurance, making semaglutide therapy accessible regardless of coverage status
The programme is everything around the medicine: the quality of the clinical assessment, who reviews your case, whether anyone checks in with you, how side effects are managed, what happens when progress stalls, and what support exists when you want to stop
Backed by our 4-month results guarantee .
screens for specific #inherited conditions (like #cystic #fibrosis) PGT-SR: #structural rearrangements
